Detalhe da pesquisa
1.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Clin Lymphoma Myeloma Leuk;
20(11): e910-e925, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32912820